Vivli’s Post

From Lab Bench to Legacy: Unveiling the Impact of Dr. E Premkumar Reddy (Part 2 is Here!) The scientific journey rarely ends with a single discovery. Part 2 of "Beyond The Lab Coat" unveils the ripple effect of Dr. E. Premkumar Reddy's work, stretching far beyond the confines of research papers and laboratories. Prepare to be inspired by: •The detective work of decoding cancer: Witness Dr. Reddy's pioneering use of gene cloning, revealing the intricate link between specific mutations and different cancers. This paved the way for targeted therapies, a cornerstone of modern cancer treatment. •Diagnosing a global threat: Explore the development of Dr. Reddy's HIV diagnostic test - a story of innovation, missed opportunities, and crucial lessons learned. His work highlighted the importance of accessibility and affordability in healthcare. •From lab bench to bedside: Join Dr. Reddy on his quest to develop life-saving drugs, confronting the daunting challenges of drug development and celebrating the impact on countless lives. His tireless pursuit embodies the true spirit of translational medicine. •Beyond the microscope: Building bridges of knowledge: Witness the birth of scientific journals like Cancer Letters and Genes & Cancer, born from Dr.Reddy's desire to democratize knowledge and accelerate scientific progress. His contribution extends far beyond individual discoveries, fostering a community of learning. •The future of medicine: Looking Eastward: Explore Dr. Reddy's vision for harnessing the potential of traditional medicine combined with modern scientific tools. This isn't just a story of scientific breakthroughs, it's a testament to the enduring power of curiosity, resilience, and a deep-seated desire to make a difference. Listen to Part 2 now and be part of the legacy: https://lnkd.in/gF8Hd4vx Share your thoughts: What aspect of Dr. Reddy's journey resonates most with you? What impact do you hope science will have in the future? Tag Dr. E Premkumar Reddy and FABA to join the conversation! Dr. Jagadeesh Gandla Reddanna Pallu | Md Asadulghani | suresh pothani | Dr.P Ratnakar | Uday Saxena | Dr. SAMBASHIVA D | Ajith Kamath | G.Taru Sharma | Sithamraju Harinarayana Rao | Jayapala Reddy A V, PhD | Narayanan Kottaram | Dr. Markandeya Gorantla | Nalam Rao | Nithyakalyani Sri Rangan | Prabhat Arya | Raman Sundaram | Ranjan Chakrabarti | Sreedevi Devireddy | D. Srinivasa Reddy (DSReddy) | Suresh Poosala | Murty Upadhyayula | Vinay Nandicoori | Prof. Ts. Dr. Pasupuleti Visweswara Rao | Dr. TNG Sharma | Dr. Mamta S.K , Ph.D. #BeyondTheLabCoat #CancerResearch #Biotechnology #MolecularBiology, #HIVResearch, #DrugDevelopment

Lung nodules - not an uncommon source of angst amongst doctors & patients as one always wonders if it’s benign or malignant. The article highlights how common it is in Western Europe. I reckon it might be more common in Asia, given the highest prevalence of infections as well as nodule-mimics like granulomas. Something to consider as we advocate for more low-dose CT scans to screen for lung cancer. In the absence of blood tests and other biomarkers, there isn’t much more than can be done besides to watch and wait - if it’s of a small size, CT scans over a period of time help ascertain if further intervention is warranted. https://lnkd.in/g6yneMTa

Intense. That's the word that best describes Geoffrey Ling, MD's plea before Congress in support of ARPA-H. This Seal Team-like agency accelerates high-potential, high-impact biomedical and health research that cannot otherwise be funded through traditional means. Kudos to Dr. Ling! Check out his testimony here: https://lnkd.in/grcUZMUp

Happy to share our collaborative research with SK Life Science Labs, on the selective and orally efficacious SMARCA2 degraders at #AACR "Abstract 4506: Abstract 4506: Discovery of potent, highly selective and orally efficacious SMARCA2 degraders Link for the abstract: https://lnkd.in/gZYvdS52

🫁 Lung Research News! Every American Lung Association funded publication is summarized in plain language on our site! Read the latest in Lung Cancer, COPD, Asthma research, and more! Now with Headlines! https://lnkd.in/g9VBQ--4

Going to AMP? Come hear about the upcoming version of variant classification guidelines we have been working on!

Dispelling the myth that we're far from understanding MPN progression, MPN Research Foundation is at the forefront, driving collaboration across institutions to unlock the mysteries of MPN progression to acute myeloid leukemia (AML).  One of our funded Thrive initiatives, led by Dr. John Crispino in partnership with co-PI, Dr. Ayalew Tefferi of Mayo Clinic, and esteemed collaborators Drs. Charlotte Brierly, Adam Mead, and Beth Psaila, targets the DYRK1A gene on chromosome 21.   This collaborative research uncovers its amplification as a key factor in MPN to AML progression, demonstrating the power of cross-institutional collaboration in advancing our understanding of MPNs.  Supported by our 2022 Thrive award, this study exemplifies our commitment to not just understanding but also interrupting the progression of MPNs, signaling a pivotal leap towards enhancing patient outcomes.  We invite industry professionals and researchers to join our community, gaining insight into the impactful projects we fund and access to the MPN community and foundation-funded research. Together, we can foster groundbreaking discoveries and transformative solutions in the battle against MPNs.  Learn more about our collaborative efforts and how you can be part of this pioneering journey. [ https://lnkd.in/gEfTRRp2 ] Join our community to stay up to date on the latest in MPN funded research, clinical trial highlights, and more: [

Did you know there’s more on Vivli than just clinical trial data? Find out more about what's available in our repository of nearly 7,000 studies, and how you can access data that will take your research further: https://lnkd.in/es33eG_d

📆 Save the Date: April 9-11, 2025 🌆 Salt Lake City, Utah 🌟 12th Annual Cholangiocarcinoma Foundation Conference 🌎 International Consensus on Research Priorities The upcoming Annual Conference is a unique opportunity for patients and caregivers to sit side-by-side with experts in the field and provide their voices in helping focus research priorities. It is an effort between CCF’s International Cholangiocarcinoma Research Network (ICRN) and the European Cooperation in Science and Technology (COST)-Action: BTC Precision Network, part of the European Network for the Study of Cholangiocarcinoma. 🤝 The initiative brings together patients, caregivers, advocates, oncologists, researchers, industry, young investigators, regulators, and other specialists worldwide to review scientific evidence, share insights, and reach a consensus, or full agreement, on the research focus going forward to optimize existing funding and attract new funding. 🔬 Developing research priorities is crucial, and it is vital that we have the voices of patients, caregivers, advocates, and the scientific community. We hope to see you all there! 📝 Sign up for updates here: https://lnkd.in/g2rZwqKU #CCFAC25 #SLC #CureCCA #oncologyresearch #rarecancer #younginvestigators #patientadvocacy #caregiversupport #CCAHope